Study of hidden HIV in people on Biktarvy
Part of Infections clinical trials.
This study measures the “hidden” HIV reservoir in the body and how it relates to blood levels of antiretroviral medicines. It may help doctors better understand why HIV can remain even when the virus is controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man living with HIV (HIV-1), age 18 or older
- You are currently taking Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) as your first treatment, and it has been stable
- Your HIV viral load is very low: under 50 copies/mL, checked at 6 months and confirmed again at 12 months after starting treatment
- Your blood counts and related lab tests (including platelets) are normal at screening
- You can sign informed consent to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This study looks at why HIV remains in the body even when treatment is working well. You would have a colonoscopy (already scheduled for medical reasons) and allow the research team to take extra tissue samples to study how the virus hides in the gut.
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.